However, two BCR heavy chain clonotypes showed a similar level of reactivity to the omicron RBD. The other three clonotypes showed minimal or reduced reactivity to the omicron RBD before the third ...

Lonza’s bYlok® technology is changing the way bispecific antibodies are designed. Achieving the correct heterodimerization of light and heavy chains during bispecific production can be challenging, ...